Achieve Life says last subject’s last visit complete for Phase 3 ORCA-3 trial

Achieve Life Sciences announced that the last study follow-up visit for the last subject enrolled in the Phase 3 ORCA-3 trial has occurred. "We are pleased to have reached this final milestone in the Phase 3 ORCA-3 trial and continue to expect topline data results from this trial, as well as results from the ORCA-V1 trial of cytisinicline as a treatment for e-cigarette cessation, to be reported in the second quarter of this year," commented John Bencich, Chief Executive Officer of Achieve. The ORCA-3 trial randomized 792 subjects across 20 clinical locations in the United States.